RVMD Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

$18.86  -0.31 (-1.62%)
As of 06/24/2022 15:59:58 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/13/2020
Outstanding shares:  74,245,139
Average volume:  966,763
Market cap:   $1,423,279,315
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BL71K91
Valuation   (See tab for details)
PE ratio:   -6.75
PB ratio:   2.54
PS ratio:   53.03
Return on equity:   -37.67%
Net income %:   -773.42%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy